304P Incidence and resolution of eribulin-induced peripheral neuropathy (IRENE) in patients with locally advanced or metastatic breast cancer

M Schmidt,C Jackisch,T Hesse,O Hoffmann,B.J Heinrich,T-W Park-Simon,E-M Grischke,R Weide,H Müller-Huesmann,M Welslau,J Wu,H Schmitz,C Engelbrecht,H-J Lück

doi:10.1016/j.annonc.2021.08.587

304P Incidence and resolution of eribulin-induced peripheral neuropathy (IRENE) in patients with locally advanced or metastatic breast cancer

M Schmidt, C Jackisch + Show 12 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.587

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
License type: publisher-specific-oa

Affiliation: Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie, Johannes Gutenberg University Mainz, Sana Klinikum Offenbach, Agaplesion Diakonieklinikum Rotenburg, Essen University Hospital, Hannover Re (Germany), Universitäts Frauenklinik, Praxis für Hämatologie und Onkologie, Brüderkrankenhaus St. Josef Paderborn, Klinikum Aschaffenburg, Eisai (United States), Eisai (Germany)

#Incidence Of Peripheral Neuropathy #Metastatic Breast Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Eribulin (ERI), a halichondrin-class microtubule dynamics inhibitor, is a typical chemotherapeutic regimen for patients (pts) with previously treated locally advanced or metastatic breast cancer (MBC). Results of pivotal trials showed that about one-third of pts with locally advanced or MBC treated with ERI develop peripheral neuropathy (PN), a common risk with BC chemotherapies. This postauthorization safety study assessed the incidence and severity of ERI-induced PN (EIPN) in pts with locally advanced or MBC.

Full Text